// App-Quantinova.ai

: DRES-10. TEMOZOLOMIDE-ASSOCIATED HYPERMUTATION DETECTED WITH A GENE PANEL SIGNATURE IMPROVES IMMUNE RESPONSE IN GLIOBLASTOMA

Researchers

Presenter

  • Paul Daniel

Principal Investigators

  • Brian Meehan

  • Siham Sabri

  • Jann Sarkaria

  • Janusz Rak

  • Bassam Abdulkarim

Medical Centers

  • Montreal University, Montreal, QC, Canada

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • High-Grade Gliomas

  • Glioblastoma

  • Brain cancer

  • Gliomas

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 206

  • Microsatellite instability

Drug/Treatment

  • Temozolomide

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved